Strategic Thrusts Banner
Engineering CELLS,
   Engineering RESPONSES
30
Oct 2017

Roquette Opens Innovation Centre In Singapore, Asia Pacific Food Industry

French plant-based ingredients maker Roquette opened its regional headquarters and a innovation centre in Singapore as it steps up its focus on Asian growth. Roquette said its over 1,100 sqm new innovation centre at Biopolis will allow the company to partner with customers, universities and research institutions, such as Singapore's Agency for Science, Technology and Research (A*STAR) or the National University of Singapore. A*STAR chairman Lim Chuan Poh who was guest of honour at the opening, noted that Singapore is home to the R&D centres of some of the world's largest food, nutrition and pharmaceutical companies like Nestle. Mr Lim also announced tie-ups between Roquette and A*STAR's Bioprocessing Technology Institute (BTI) and Clinical Nutrition Research Centre (CNRC) to look at issues such as how different Asian populations react to certain dietary ingredients.

27
Oct 2017

French MNC opens regional HQ in Singapore, The Straits Times

French plant-based ingredients maker Roquette opened its regional headquarters and innovation centre in Singapore as it steps up its focus on Asian growth. Roquette said its over 1,100 sqm new innovation centre at Biopolis will allow the company to partner with customers, universities and research institutions, such as Singapore's Agency for Science, Technology and Research (A*STAR) or the National University of Singapore. A*STAR chairman Lim Chuan Poh who was guest of honour at the opening, noted that Singapore is home to the R&D centres of some of the world's largest food, nutrition and pharmaceutical companies like Nestle. Mr Lim also announced tie-ups between Roquette and A*STAR's Bioprocessing Technology Institute (BTI) and Clinical Nutrition Research Centre (CNRC) to look at issues such as how different Asian populations react to certain dietary ingredients.

28
Jun 2017

Study Pinpoints Best Stage of Stem Cell Differentiation for Use in Treating Parkinson’s Disease, PR Webs

Studies indicate that replacing damaged brain cells with those derived from human embryonic stem cells might lead to an effective treatment for Parkinson’s disease. A new study coming out of Singapore, recently published in STEM CELLS Translational Medicine journal addresses the optimal stage that the transplantation of differentiation of stem cells should take place in order to gain the best results. The study is co-led by the National Neuroscience Institute, Singapore (NNI) and the Agency for Science, Technology and Research (A*STAR).

19
Apr 2017

Red blood cells derived from stem cells could offer a limitless supply for transfusions, Medical Xpress

Researchers from A*STAR's Bioprocessing Technology Institute (BTI) have grown red blood cells (RBCs) from stem cells in an efficient and reliable way. Lab-grown blood offers a potentially limitless solution, but existing methods for manufacturing blood from stem cells are not appropriate for clinical use. Jaichandran and his colleagues got around these problems by using tiny plastic spheres known as microcarriers. These spheres float in suspension, providing large amounts of surface area. And covering them in a human protein called laminin-521 eliminates the need for any animal material. By culturing the stem cells on these microcarriers and adjusting the media, the A*STAR team could generate at least six times as many RBC precursor cells and 80 times as many differentiated RBCs as the standard method involving embryoid bodies in a dish. Since reporting the method last year, the researchers have boosted the yields even further.

18
Apr 2017

Taking the sting out of bone repair, Science Daily

Researchers at A*STAR's Bioprocessing Technology Institute (BTI) and Institute of Materials Research and Engineering (IMRE) have developed small biodegradable and biocompatible supports that aid stem cell differentiation and multiplication as well as bone formation in living animal models. Existing approaches to expand stem cells for industrial applications tend to use two-dimensional materials as culture media, but their production yields are too low for clinical demand. Furthermore, stem cells typically need to be harvested with enzymes and attached to a scaffold before they can be implanted. To bring commercially viable cell therapies to market, Asha Shekaran and Steve Oh, from BTI, have created directly implantable microscopic spheres in collaboration with IMRE. These spheres, which acted as heMSC microcarriers, consist of a biodegradable and biocompatible polymer called polycaprolactone.

07
Apr 2017

Stem cells: Single-use bioreactors and microcarriers can overcome scale-up issues, experts, Bio Pharma

The only practical way to scale-up volumes of mesenchymal stem cells (MSCs) is by using microcarriers in single-use bioreactors, say scientists from A*STAR and Instituto Superior Técnico. Dr Steve Oh, principal scientist and associate director at A*STAR's Bioprocessing Technology Institute (BTI), said that a similar set-up had shown promise in moving MSC cultivation into scalable technologies and his team is trying to move to a 15L scale. However, the goal for MSC-based therapies would be producing commercial volumes of '10,000 doses per year, each of billion cells' from the onset.

17
Mar 2017

Waters Honours Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Research, Labmate Online

Waters Corporation will be assisting A*STAR's Bioprocessing Technology Institute (BTI) in its glycoscience research. BTI is the first research institute focused on glycobiology to participate in the Waters Centers of Innovation Program. BTI’s glycan research is aimed at finding novel cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies. According to Dr. Mike Harrington, senior vice president, global markets for Waters Corporation, BTI’s research in glycobiology is world-class and they wish to help it realize the enormous potential of this very important area of science through the application of Waters analytical technologies and expertise.

08
Mar 2017

Waters Honors Singapore’s Bioprocessing Technology Institute for Glycoscience Research, Technology Networks

Waters Corporation will be assisting A*STAR's Bioprocessing Technology Institute (BTI) in its glycoscience research. BTI is the first research institute focused on glycobiology to participate in the Waters Centers of Innovation Program. BTI’s glycan research is aimed at finding novel cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies. According to Dr. Mike Harrington, senior vice president, global markets for Waters Corporation, BTI’s research in glycobiology is world-class and they wish to help it realize the enormous potential of this very important area of science through the application of Waters analytical technologies and expertise.

07
Mar 2017

Waters to chip in expertise for Singapore’s Bioprocessing Technology Institute in glycoscience research, Pharma Biz

Waters Corporation will be assisting A*STAR's Bioprocessing Technology Institute (BTI) in its glycoscience research. BTI is the first research institute focused on glycobiology to participate in the Waters Centers of Innovation Program. BTI’s glycan research is aimed at finding novel cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies. According to Dr. Mike Harrington, senior vice president, global markets for Waters Corporation, BTI’s research in glycobiology is world-class and they wish to help it realize the enormous potential of this very important area of science through the application of Waters analytical technologies and expertise.

27
Feb 2017

A*STAR’s Bioprocessing Technology Institute recognised as the Centre of Innovation by Waters Corporation, A*STAR Website

A*STAR’s Bioprocessing Technology Institute (BTI) has been recognised by Waters Corporation as the Centre of Innovation on 27 Feb 2017. BTI is the first research institute focused on glycobiology to participate in Waters’ Centers of Innovation Program. Its glycan research is aimed at finding novel cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies.

27
Feb 2017

Waters Honors Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Research, Yahoo Online

At a ceremony and symposium today, Waters Corporation welcomed into its Centers of Innovation Program the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR). BTI is the first research institute that focused on glycobiology to participate in the Waters Centers of Innovation Program. Glycans, or sugars, are one of the four fundamental classes of macromolecules that comprise living systems. BTI’s glycan research is aimed at finding novel cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies.

27
Feb 2017

Waters Honors Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Research, Bloomberg

At a ceremony and symposium today, Waters Corporation (NYSE:WAT) welcomed into its Centers of Innovation Program the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR). BTI is the first research institute focused on glycobiology to participate in the Waters Centers of Innovation Program.

27
Feb 2017

Waters Honors Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Research, BusinessWire

At a ceremony and symposium today, Waters Corporation welcomed into its Centers of Innovation Program the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR). BTI is the first research institute that focused on glycobiology to participate in the Waters Centers of Innovation Program.

27
Feb 2017

Waters Honors Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Research, WallStreet Online

At a ceremony and symposium today, Waters Corporation (NYSE:WAT) welcomed into its Centers of Innovation Program the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR). BTI is the first research institute focused on glycobiology to participate in the Waters Centers of Innovation Program.

27
Feb 2017

Waters Honors Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Research, The New York Times

At a ceremony and symposium today, Waters Corporation (NYSE:WAT) welcomed into its Centers of Innovation Program the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR). BTI is the first research institute focused on glycobiology to participate in the Waters Centers of Innovation Program.

27
Feb 2017

Waters Honors Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Research, MFR Tech

At a ceremony and symposium today, Waters Corporation welcomed into its Centers of Innovation Program the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR). BTI is the first research institute that focused on glycobiology to participate in the Waters Centers of Innovation Program. Glycans, or sugars, are one of the four fundamental classes of macromolecules that comprise living systems. BTI’s glycan research is aimed at finding novel cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies.

04
Oct 2016

We are looking to collaborate with visionary research institutes to develop new methods of discovering cancer, Bio Spectrum

Waters Corporation recently collaborated with the Bioprocessing Technology Institute (BTI), a research institute within Singapore's Agency for Science, Technology and Research (A*STAR), to develop new methods of finding cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic cancer strategies. In an interview with BioSpectrum Asia, Dr Jose Castro-Perez, Director of Health Sciences Marketing at Waters shares more about the objective of this partnership and how significant it is for the biotech research landscape in Singapore.

19
Sep 2016

Business prizes: Winning firms lauded for tech focus, The Straits Times

MiRXES, A*STAR spinoff, won the Most Promising Startup at 2016 Emerging Enterprise Awards (EE 2016). The startup aims to revolutionise cancer detection by offering affordable blood test kits in place of current diagnostic methods. MiRXES took home the award and $30,000 worth digital of consultancy services from Maxus.

19
Sep 2016

Women behind EE winner's success, The Business Times

MiRXES, A*STAR spinoff, won the Most Promising Startup at 2016 Emerging Enterprise Awards (EE 2016). The startup aims to revolutionise cancer detection by offering affordable blood test kits in place of current diagnostic methods. MiRXES took home the award and $30,000 worth digital of consultancy services from Maxus.

02
Sep 2016

Zika outbreak: Warriors in lab coats, The Straits Times

As news on Zika continues to unfold, A*STAR’s Zika team and their research are highlighted in the media at the forefront of Singapore’s R&D efforts to diagnose and understand the disease. Coverage on A*STAR’s diagnostic test kit continues. The kit can simultaneously test for Zika, dengue and chikungunya is ready for use. The kit delivers results in a space of up to two hours, and offers advantages in a region where all three mosquito-borne diseases are present. A*STAR is also developing an antibody test to detect whether a person has been infected with the virus, even after it is no longer detected in the blood.

02
Aug 2016

Novel Peptide Found to Kill Breast Cancer, Leave Healthy Tissue Unharmed, Breast Cancer News

A newly found peptide that can kill tumor cells while sparing healthy cells could be an effective therapeutic strategy, when combined with other drugs, for drug-resistant cancers such as breast cancer, according to the study, “Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy,” published in the latest edition of the journal Oncotarget.

22
Jul 2016

Waters Collaborate with BTI on Glycosphingolipid Project, Chromatography Online

Waters Corporation (Massachusetts, USA) has announced a collaboration with the Bioprocessing Technology Institute (BTI), a research institute within Singapore’s Agency for Science, Technology, and Research (A*STAR). The joint effort will develop a glycosphingolipid (GSL) head group database containing Glucose Unit (GU) retention times1 and collision cross-section (CCS) values, forming an experimental library for disease related GSL glycans together with a glycan/MS spectral library. GSLs constitute a glycan head group attached to fatty acyl moieties, and are critical for cell growth interaction, and signalling. Alterations to their structure can cause disease or promote cancer development, however, analysis of glycan head groups has proved difficult because their isomeric structures are not easily differentiated by either liquid chromatography (LC) or mass spectrometry (MS) when used alone.

23
Jun 2016

Waters collaborates with A*star to expand biomarker discovery, BioSpectrum

Waters Corporation has collaborated with Bioprocessing Technology Institute (BTI), a research institute within Singapore's Agency for Science, Technology and Research (A*STAR), to develop new methods of finding cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies. As part of the research collaboration, Waters and BTI will develop a glycosphingolipid (GSL) head group database containing Glucose Unit (GU) retention times and collision cross-section (CCS) values in an effort to compile an experimental library for disease-related GSL glycans together with a glycan/MS spectral library.

22
Jun 2016

Waters and Singapore’s BTI Collaborate to Identify Cancer Markers, Sonoran Weekly Review

Waters (NYSE:WAT) will work with the Bioprocessing Technology Institute in Singapore’s Agency for Science, Technology and Research to develop ways of finding cancer markers and elucidating glycosylation pathways for new therapeutic strategies. Waters and BTI will develop a glycosphingolipid head group database containing glucose unit retention times and collision cross-section values. “GSLs are critical for cell growth, interaction, and signaling and alterations to their structure may result in diseases or promote the development of different types of cancer,” the company said.

21
Jun 2016

Waters Collaborates with Singapore’s Bioprocessing Technology Institute to Develop New Strategies to Identify Cancer Markers and Probe Cancer Biology, Business Wire

Waters Corporation (NYSE:WAT) today announced a joint effort with the Bioprocessing Technology Institute (BTI), a research institute within Singapore's Agency for Science, Technology and Research (A*STAR), to develop new methods of finding cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies.

21
Jun 2016

Waters Collaborates with Singapore’s Bioprocessing Technology Institute to Develop New Strategies to Identify Cancer Markers and Probe Cancer Biology Waters Corporation, Pharmi Web

Waters Corporation (NYSE:WAT) today announced a joint effort with the Bioprocessing Technology Institute (BTI), a research institute within Singapore's Agency for Science, Technology and Research (A*STAR), to develop new methods of finding cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies.

15
Jun 2016

The Zika alliance, A*STAR Research

Chikungunya, dengue and Zika viruses are transmitted by the same mosquito species — Aedes Aegypti and Aedes albopictus — and exhibit similar symptoms in infected patients. But, compared with the painful fever, headache and joint pain often associated with chikungunya, which means ‘to walk bent over’ in the Kimakonde language, and dengue, also known as ‘breakbone’ or ‘breakheart’ fever, Zika is like a mild flu, and often comes and goes unnoticed.

21
Mar 2016

Screening for early stage stomach cancer with a blood test, Biotech In Asia

Researchers from MirXES, have come up with a screening procedure which involves a simple blood test to detect early stage stomach cancer, a killer disease that affects more than 70,000 people every year in Asia. MicroRNAs are a class of non-coding RNAs that play key roles in the regulation of gene expression. MicroRNAs usually induce gene silencing by binding to the 3′ UTR regions of the targeted mRNAs. This coupled with the fact that circulating miRNAs are stable, make them ideal candidates to serve as diagnostic markers and also for treatment response monitoring.

08
Mar 2016

SCIEX and A*STAR’s Bioprocessing Technology Institute Enter Multi-Year Collaboration to Advance Biologics R&D in Singapore, Biotech in Asia

SCIEX, a global leader in life science analytical technologies, and the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR) with expertise in bioprocess science and engineering, today announced a collaboration to advance research and development in the area of biologics in Singapore.

03
Mar 2016

Tracking the Developments in the Cellular and Gene Therapy Industry, PRNewswire

The cellular and gene therapy industry has seen quite a lot of developments in the last decade, majorly driven by the constant search for cures of diseases rather than their mitigation. Commercially, there have been only a few products mostly due to the economic, technical, and regulatory challenges faced for successful adoption. Laboratories play a pivotal role in clinical development and commercialization of products, and hence, should understand what industries need for effective development of products on a commercial scale.

02
Mar 2016

Lupus Patients May Benefit from Identification of RNAs that Regulate Antibodies in Mice, Lupus News Today

Researchers from Singapore’s leading science institute, A*STAR, found that a group of small noncoding RNAs, called mir-17-92, regulate B-cell function and antibodies in mice. The results may help pave the way for new lupus treatments and other diseases linked to B-cell dysfunction. Antibody-producing B-cells are a crucial part of our defense against pathogens. In autoimmune diseases such as systemic lupus erythematosus (SLE), antibodies are directed at the body’s own proteins. Researchers have known that mir-17-92 regulates the early development of B-cells, but the RNA cluster’s role in mature B-cells has been elusive.

12
Feb 2016

Screen for stomach cancer with a blood test, The Straits Times

A blood test to assess early-stage stomach cancer, a major killer here, could be rolled out in local hospitals as soon as next year . Instead of going for an uncomfortable endoscopy to see if they are at risk, patients can first take the blood test to see whether more detailed tests are needed. The diagnostic kit is the brainchild of MiRXES - a spin-off by researchers from the Agency for Science, Technology and Research (A*Star). With just a few drops of blood, doctors are able to detect accurately whether a patient has developed early-stage gastric cancer.

01
Feb 2016

Sciex, A*STAR to collaborate on advance biologics research & development in Singapore, The Pharma Letter

Research services company Sciex said it has signed a biologics research and development collaboration with Bioprocessing Technology Institute (BTI), a research institute under Singapore's Agency for Science, Technology and Research (A*STAR). Under the terms of the deal, Sciex will provide BTI with its reliable, sensitive and intuitive instruments including the TripleTOF 6600 system and a Nano LC system, along with Sciex software, and support from a team of application experts to assist with the analysis of complex contaminant protein molecules related to the production and analysis of biologic drugs.

28
Jan 2016

SCIEX, A*STAR’s BTI collaborate to advance biologics research & development in Singapore, Pharma Biz

SCIEX, a global leader in life science analytical technologies, and the Bioprocessing Technology Institute (BTI), a research institute under Singapore's Agency for Science, Technology and Research (A*STAR) with expertise in bioprocess science and engineering, today announced a collaboration to advance research and development in the area of biologics in Singapore. The collaboration aims to meet the needs of the biopharmaceutical industry in developing accurate and high-throughput methods for analysis of these contaminants, to help the industry validate therapeutic candidates and ensure the safety and efficacy of biologics according to established regulatory guidelines.

26
Jan 2016

SCIEX and A*STAR’s Bioprocessing Technology Institute Enter Multi-Year Collaboration to Advance Biologics Research & Development in Singapore, Business Wire

SCIEX, a global leader in life science analytical technologies, and the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR) with expertise in bioprocess science and engineering, today announced a collaboration to advance research and development in the area of biologics in Singapore.